Clinical Trial Search

Primary: Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52 — 50.65; 58.71; 5.35; 5.96 units on a scale — p=0.8595

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks — -20.2; -10.8 mg/dL non-HDL cholesterol

Primary: Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score — 87.57; 88.74; 85.88; 91.68 scores on a scale

Primary: Time to Relapse of Psychotic Symptoms During 6 Weeks — 23.8; 16.9; 17.3 days

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: Mean Change From Baseline to 52 Weeks in Body Mass Index (BMI) for All Participants — 3.64; 2.83 kilograms per meter squared (kg/m^2) — p=0.150

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Change in Cognition and Psychopathology Disorders as Measured on the MATRICS Consensus Cognitive Battery (MCCB) — 14.1; 14.3 units on a scale

Primary: The State Social Paranoia Scale (SSPS) — 9.72; 3.90 The change score of SSPS (pre - post) — p=0.023

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms

Primary: Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks — 6.50; 9.85 days

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 70; 35 participants

Primary: Double-blind: Percentage of Participants Who Experienced Relapse — 15.2; 33.5; 11.5; 32.9 percentage of participants — p=<0.001

Primary: Cerebral Glutamate Levels — -1.434662171; -1.933853656; -1.412294235; -1.838991525 relative unit (RU as compared to water)

Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale

Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072

Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale

Primary: Nocturnal Melatonin Production — 11.19; 19.09; 10.39; 15.18 mg/dL

Primary: Change in Positive Symptoms of Schizophrenia — 22.6; 24.2 units on a scale

Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02

Primary: Total Plasmalogen Levels in the Lipid Profile — 57.65; 59.57; 75 nmoles/gram — p=0.0149

Primary: Number Who Discontinued Medication Within First 6 Study Months — 11; 23 participants

Primary: Percent Change From Baseline in Body Weight at Week 12 — 4.91; 6.77 Percentage of change in body weight — p=.012

Primary: Change in Waist Circumference — 106.09; 108.37 cm

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935